Kardegic

D,l-Lysine Acetylsalicylate, the active ingredient in Kardegic, is a nonsteroidal anti-inflammatory drug presented as an oral tablet for oral use. It is employed to reduce platelet aggregation and to help prevent arterial clot formation in patients at risk of cardiovascular events.

GNH USA supplies Kardegic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kardegic is an antiplatelet agent used in several cardiovascular and cerebrovascular conditions. - Prevention of arterial thrombosis: lowers the risk of clot formation in arteries. - Secondary prevention after myocardial infarction: reduces recurrence of heart attacks. - Stroke prevention: diminishes the chance of ischemic stroke in high‑risk patients. - Management of acute coronary syndrome: supports early treatment to limit platelet‑driven occlusion.

Adverse reactions may occur with any antiplatelet therapy.

Common Side Effects: - Dyspepsia or stomach discomfort: mild gastrointestinal irritation. - Nausea: occasional feeling of queasiness. - Abdominal pain: transient cramping. - Increased minor bleeding: easy bruising or prolonged bleeding from cuts.

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding: severe hemorrhage requiring medical attention. - Hemorrhagic stroke: intracranial bleeding with neurological deficits. - Allergic reactions: rash, angioedema, or anaphylaxis. - Severe asthma exacerbation: bronchospasm in aspirin‑sensitive individuals. - Renal impairment: reduced kidney function in susceptible patients.

Before initiating therapy, consider the following safety measures. - Assess bleeding risk: review history of ulcers, surgery, or anticoagulant use. - Avoid in active peptic ulcer disease: contraindicated due to ulcer aggravation. - Monitor renal function: adjust use if significant impairment is present. - Use caution in asthma: may trigger bronchospasm in aspirin‑sensitive patients. - Store at ambient temperature: keep in the original pack, protect from moisture.

Kardegic can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Other NSAIDs: additive gastrointestinal toxicity. - Corticosteroids: increased ulceration potential. - Selective serotonin reuptake inhibitors (SSRIs): amplified bleeding tendency. - Alcohol: synergistic effect on gastric mucosa and bleeding.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: possible reduction in antihypertensive effect. - Diuretics: may affect renal clearance. - Lithium: increased lithium levels. - Methotrexate: reduced renal elimination, risk of toxicity. - Oral hypoglycemics: potential enhancement of hypoglycemic effect.